MX356427B - Emulsion que contiene hormona. - Google Patents

Emulsion que contiene hormona.

Info

Publication number
MX356427B
MX356427B MX2014010442A MX2014010442A MX356427B MX 356427 B MX356427 B MX 356427B MX 2014010442 A MX2014010442 A MX 2014010442A MX 2014010442 A MX2014010442 A MX 2014010442A MX 356427 B MX356427 B MX 356427B
Authority
MX
Mexico
Prior art keywords
fatty acids
hormone containing
containing emulsion
fish oil
hormone
Prior art date
Application number
MX2014010442A
Other languages
English (en)
Other versions
MX2014010442A (es
Inventor
Kaspar Ilona
Krüger Volker
Röthlein Doris
Wolf Martin
Schmitt Jürgen
Original Assignee
Braun Melsungen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braun Melsungen Ag filed Critical Braun Melsungen Ag
Publication of MX2014010442A publication Critical patent/MX2014010442A/es
Publication of MX356427B publication Critical patent/MX356427B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una emulsión de aceite en agua que contiene hormona para administración parenteral, que comprende (a) progestágeno y/o estrógeno; y (b) triglicéridos de aceite de pescado, en donde los triglicéridos de aceite de pescado consisten en glicerol que está esterificado con ácidos grasos, en donde dichos ácidos grasos comprenden ácido eicosapentaenoico (EPA) y ácido docosahexaenoico (DHA), en una cantidad de por lo menos 45% en peso de dichos ácidos grasos.
MX2014010442A 2012-02-29 2013-02-25 Emulsion que contiene hormona. MX356427B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12157546 2012-02-29
PCT/EP2013/053686 WO2013127728A1 (en) 2012-02-29 2013-02-25 Hormone containing emulsion

Publications (2)

Publication Number Publication Date
MX2014010442A MX2014010442A (es) 2014-10-13
MX356427B true MX356427B (es) 2018-05-29

Family

ID=47748635

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010442A MX356427B (es) 2012-02-29 2013-02-25 Emulsion que contiene hormona.
MX2014010445A MX2014010445A (es) 2012-02-29 2013-02-25 Emulsion que contiene hormona que comprende fosfolipidos de kril.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014010445A MX2014010445A (es) 2012-02-29 2013-02-25 Emulsion que contiene hormona que comprende fosfolipidos de kril.

Country Status (16)

Country Link
US (2) US9789122B2 (es)
EP (2) EP2819650A1 (es)
JP (2) JP2015508791A (es)
KR (2) KR20140131936A (es)
CN (3) CN110251463A (es)
BR (2) BR112014021390A2 (es)
CA (2) CA2865030C (es)
ES (1) ES2659466T3 (es)
IL (2) IL233759B (es)
IN (2) IN2014DN08089A (es)
MX (2) MX356427B (es)
NO (1) NO2819649T3 (es)
PL (1) PL2819649T3 (es)
PT (1) PT2819649T (es)
RU (2) RU2014139008A (es)
WO (2) WO2013127728A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2968245B1 (en) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR101588247B1 (ko) 2013-04-17 2016-01-25 경희대학교 산학협력단 뇌졸중 또는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2015053379A1 (en) * 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201402457D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
EP3232798A1 (en) 2014-12-19 2017-10-25 Aker Biomarine Antarctic AS Enhanced omega-3 formulations
CA2971786A1 (en) * 2015-03-31 2016-10-06 Fresenius Kabi Deutschland Gmbh Emulsions for parenteral administration
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN105878184A (zh) * 2016-04-26 2016-08-24 天津市中升挑战生物科技有限公司 一种四烯雌酮纳米乳液及其制备方法
US11324697B2 (en) * 2017-08-10 2022-05-10 The Children's Medical Center Corporation Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids
CN115996711A (zh) * 2020-04-15 2023-04-21 纽约市哥伦比亚大学理事会 稳定的甘油二酯乳液和治疗器官损伤的方法
WO2022125484A1 (en) * 2020-12-07 2022-06-16 The Trustees Of Columbia University In The City Of New York Compositions and methods for neuroprotection in neonatal hypoxic-ischemic encephalopathy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2738253A1 (de) 1977-08-25 1979-03-01 Dabisch Tipp Ex Tech Koerper mit reversibel temperaturabhaengiger transparenz
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
JPS60258110A (ja) 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
US5560364A (en) 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
US20100173876A1 (en) 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP1488785A1 (de) * 2003-06-18 2004-12-22 B. Braun Melsungen Ag Ölemulsion zur postnatalen Hormonsubstitution
IL158552A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1868614B1 (en) 2005-03-24 2012-08-08 Emory University Dosage regimen for the treatment of a traumatic brain injury with progesterone
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
AU2006269405B2 (en) * 2005-07-08 2013-01-17 Dsm Ip Assets B.V. Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
CA2631497C (en) 2005-12-05 2014-04-22 Bioartificial Gel Technologies Inc. Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase
WO2007080515A1 (en) 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
JP5352961B2 (ja) * 2006-03-28 2013-11-27 Ｊｎｃ株式会社 生活習慣病予防・治療剤
CN101152186B (zh) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
RU2009145010A (ru) * 2009-12-04 2011-06-20 Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) Композиция омега-3 и омега-6 полиненасыщенных жирных кислот
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US8895074B2 (en) * 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
CN102277237B (zh) * 2011-06-20 2013-04-24 山东禹王制药有限公司 一种甘油酯型鱼油的制备方法

Also Published As

Publication number Publication date
ES2659466T3 (es) 2018-03-15
PL2819649T3 (pl) 2018-06-29
CA2864945A1 (en) 2013-09-06
IL233760A0 (en) 2014-09-30
RU2678319C2 (ru) 2019-01-28
IN2014DN08089A (es) 2015-05-01
CA2865030C (en) 2021-04-27
CN110251463A (zh) 2019-09-20
KR20140131936A (ko) 2014-11-14
EP2819649A1 (en) 2015-01-07
WO2013127727A1 (en) 2013-09-06
US20150018320A1 (en) 2015-01-15
JP6169110B2 (ja) 2017-07-26
CA2865030A1 (en) 2013-09-06
IL233759A0 (en) 2014-09-30
IL233759B (en) 2019-01-31
NO2819649T3 (es) 2018-06-09
MX2014010445A (es) 2014-10-13
EP2819650A1 (en) 2015-01-07
KR102027613B1 (ko) 2019-10-01
PT2819649T (pt) 2018-02-19
RU2014139008A (ru) 2016-04-20
CN104136008A (zh) 2014-11-05
KR20140131937A (ko) 2014-11-14
WO2013127728A1 (en) 2013-09-06
US9789122B2 (en) 2017-10-17
BR112014021390A2 (pt) 2019-09-24
JP2015508791A (ja) 2015-03-23
CN104136007A (zh) 2014-11-05
BR112014021391A2 (es) 2017-06-20
MX2014010442A (es) 2014-10-13
RU2014138996A (ru) 2016-04-20
IN2014DN08088A (es) 2015-05-01
BR112014021391B1 (pt) 2022-07-26
EP2819649B1 (en) 2018-01-10
JP2015508792A (ja) 2015-03-23
US20150011515A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
MX356427B (es) Emulsion que contiene hormona.
MX2011009507A (es) Emulsiones de aceite en agua a base de pescado enriquecidas en omega-3 para nutricion parenteral.
PE20170253A1 (es) Lipido que comprende acidos grasos poliinsaturados de cadena larga
NZ626699A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
MX342216B (es) Composiciones de acidos grasos.
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
NZ631702A (en) Production of long chain polyunsaturated fatty acids in plant cells
PH12016500100B1 (en) Self-emulsifying composition of omega3 fatty acid
FR2955459B1 (fr) Composition huileuse riche en monoglycerides de dha
NZ613586A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
PH12017500074A1 (en) Nutritional compositions containing oil blends and uses thereof
NZ716730A (en) Methods, compositions, and devices for supplying dietary fatty acid needs
BR112014013593A8 (pt) retenção de dha durante o processamento de óleo de canola
EP2506848A4 (en) SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF
EA201591680A1 (ru) Смесь жирных кислот (гжк, группа жирных кислот) и её применение для лечения воспалительных патологий
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
AR076184A1 (es) Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo lipidico. metodo.
WO2011137160A3 (en) Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
UA111967C2 (uk) Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання
JP2016501249A5 (es)
MX2015007085A (es) Composiciones de acido omega-3 pentanoico y metodos de uso.
JP2016501248A5 (es)
WO2012153345A9 (en) Docosahexaenoic acid (dha) as polyunsaturated free fatty acid in its directly compressible powder form and method of isolation thereof
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
WO2009031275A1 (ja) 抗酸化剤

Legal Events

Date Code Title Description
FG Grant or registration